Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
05/2003
05/27/2003US6569905 Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
05/27/2003US6569904 Via administration of toremifene for treatment or prevention of systemic/pulmonary hypertension, fibrosis, bronchial asthma, respiratory distress syndrome, myocardial infarction, thrombosis, congestive heart failure, and renal failure
05/27/2003US6569890 Cyclic AMP-specific phosphodiesterase inhibitors
05/27/2003US6569888 Such as ethyl-N-(dichlorobenzyl)-4-(3-hydroxypropylthio) indole-2-carboxylate; for treatment of arthritis
05/27/2003US6569885 Cyclic AMP-specific phosphodiesterase inhibitors
05/27/2003US6569876 Method and structure for inhibiting activity of serine elastases
05/27/2003US6569871 Substituted imidazole compounds
05/27/2003US6569861 Melanin concentrating hormone receptor ligands
05/27/2003US6569860 Alkoxycarbonylamino-heteroaryl carboxylic acid derivatives useful for treating the disorders of the urinary tract, pain, inflammation, respiratory states, edema formation, hypotensive vascular diseases, pain and allergies
05/27/2003US6569855 Particularly zinc metalloprotease activity for treatment of variety of maladies involving inflammation and/or tissue integrity
05/27/2003US6569847 Inhibitors of cathepsins for treating muscular dystrophy, osteoporosis, rheumatoid arthritis, neuronal or cardiac ischaemia, allergy, or Chagas disease
05/27/2003US6569835 Hypolipidemics; treating obesity and disorders of lipid metabolism
05/27/2003US6569665 Genetic engineering; enzymatic inhibitor screening; use of calpain inhibitors in treatment of neurodegenerative disease
05/27/2003US6569463 Encapsulation coat includes different combinations of pharmaceutical active ingredients, hydrophilic and lipophilic surfactants, and triglycerides
05/27/2003US6569446 Solubilization of flavonols
05/27/2003US6569434 Vascular endothelial cell growth factor C subunit
05/27/2003US6569075 Lipoxin compounds and their use in treating cell proliferative disorders
05/27/2003CA2412624A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurogenerative diseases
05/27/2003CA2412466A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
05/27/2003CA2274241C A process for purifying apolipoprotein a or apolipoprotein e from human plasma
05/27/2003CA2231558C .gamma.-rar antagonist ligand or .alpha.-rar agonist ligand as an apoptosis inhibitor
05/27/2003CA2084961C Tissue protective tocopherol analogs
05/27/2003CA2066104C Benzazepine derivatives as vasopressin antagonists
05/22/2003WO2003042397A2 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
05/22/2003WO2003042390A1 Mammalian protein phosphatases
05/22/2003WO2003042362A2 PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
05/22/2003WO2003042359A2 Histamine receptor h3 polynucleotides
05/22/2003WO2003042358A2 Methods of using 48149, a human aminopeptidase family member
05/22/2003WO2003042357A2 Enzymes
05/22/2003WO2003042218A1 Novel compounds
05/22/2003WO2003042216A1 Polycyclic guanine derivative phosphodiesterase v inhibitors
05/22/2003WO2003042214A2 A2b adenosine receptor antagonists
05/22/2003WO2003042213A1 Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
05/22/2003WO2003042211A1 Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase
05/22/2003WO2003042208A1 Pyrazole derivatives as psychopharmaceuticals
05/22/2003WO2003042207A1 Thiazolyl substituted triazoles as alk5 inhibitors
05/22/2003WO2003042206A1 Pyridinone and pyrimidinone compounds
05/22/2003WO2003042205A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003WO2003042194A1 Carboxylic acid derivative compounds and drugs containing the same as the active ingredient
05/22/2003WO2003042191A1 Benzamide and heteroarylamide as p2x7 receptor antagonists
05/22/2003WO2003042190A1 N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
05/22/2003WO2003042179A1 Heterocyclic derivatives of glycinamide and their medical use
05/22/2003WO2003042178A1 Novel piperidine derivatives as modulators of chemokine receptors
05/22/2003WO2003042177A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003WO2003042174A1 Cannabinoid receptor ligands
05/22/2003WO2003042173A1 Nk1 antagonists
05/22/2003WO2003042165A1 Formoterol tartrate process and polymorph
05/22/2003WO2003042164A1 Aryl aniline beta-2 adrenergic receptor agonists
05/22/2003WO2003042113A1 Production of cell suspensions
05/22/2003WO2003041736A2 Method for the treatment of cardiotoxicity induced by antitumor compounds
05/22/2003WO2003041725A2 Regulation of cgmp-specific phosphodiesterase 9a
05/22/2003WO2003041722A1 Use of specific dose of fondaparinux sodium for the treatment of acs
05/22/2003WO2003041713A1 Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
05/22/2003WO2003041712A1 Pyridone, pyridazone and triazone derivatives as lp-pla2 inhibitors
05/22/2003WO2003041711A1 Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor
05/22/2003WO2003041707A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
05/22/2003WO2003041697A1 Method for treating autoimmune diseases
05/22/2003WO2003041696A1 Methods and compositions for use of (s)-bisoprolol
05/22/2003WO2003041684A2 Injectable depot compositions and uses thereof
05/22/2003WO2003041563A2 Neurotransmitter balance chemotherapy
05/22/2003WO2003015695A3 Canine cardiac diet
05/22/2003WO2003013498A3 Nitrate ester-cyclodextrin complexes for treating diseases, particularly coronary diseases
05/22/2003WO2002100327A3 Substituted 1-benzazepines and derivatives thereof
05/22/2003WO2002098438A9 Compositions containing an active fraction isolated from scutellariae barbatae and methods of use
05/22/2003WO2002097116A3 Delivery system for nucleic acids
05/22/2003WO2002096362A3 Method for treating fibrotic diseases or other indications vi
05/22/2003WO2002084288A3 Individualization of therapy with antiarrhythmics
05/22/2003WO2002060419A3 A substance for use in a dietary supplement or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
05/22/2003WO2002053141A3 Inhibition of angiogenesis by nucleic acids
05/22/2003WO2002044183A3 Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
05/22/2003WO2002044168A3 Indole-type inhibitors of p38 kinase
05/22/2003WO2002030924A9 Quinazoline derivatives with anti-tumour activity
05/22/2003WO2000037429A3 INHIBITORS OF α4β1 MEDIATED CELL ADHESION
05/22/2003US20030097023 For prophylaxis and therapy of immunological diseases, asthma, abnormal bone formation, neuronal cell death, lung failure, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardiac ischemia
05/22/2003US20030097004 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists
05/22/2003US20030097000 2-Phenyl-quinoline derivatives, preparation method and therapeutic use thereof
05/22/2003US20030096992 Method of preparing alkylated salicylamides via a dicarboxylate intermediate
05/22/2003US20030096982 Nucleotide sequences coding polypeptide for use in the treatment of immunological, reproductive and liver disorders
05/22/2003US20030096859 Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
05/22/2003US20030096858 The parent drug compound is modified by forming one or more of predetermined chemical arrangement within parent drug structure for programming specific course and rate of metabolism for drug that leads to inactive nontoxic metabolite
05/22/2003US20030096852 Inhibiting binding interaction between hGH (human growth hormone) or a mutant thereof and an hGH binding protein or receptor in mammal administering benzimidazole compound
05/22/2003US20030096844 Cannabinoid receptor ligands
05/22/2003US20030096841 For treatment of cancers, heart disease, such as congestive heart failure, osteoporosis, genetic, inflammatory, allergic, and autoimmune diseases
05/22/2003US20030096838 Novel triazolo-pyridines anti-inflammatory compounds
05/22/2003US20030096833 Use in inhibiting inflammation, cell death and in treating shock and reperfusion injuries
05/22/2003US20030096829 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors
05/22/2003US20030096827 Heterocyclic amine derivatives; for treating an inflammatory or immune disease, a cardiovascular disease, or a neurodegenerative condition
05/22/2003US20030096826 Inhibitors of interleukin-1 beta converting enzyme and other cysteine proteases in the ICE family
05/22/2003US20030096824 Substituted phenylamidines medicaments containing said compounds and method for production thereof
05/22/2003US20030096823 Method for the treatment of cardiotoxicity induced by antitumor compounds
05/22/2003US20030096819 Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents
05/22/2003US20030096817 Inhibiting mammalian protein kinases (p38) with (2,6-difluoro-phenyl)-(5-iodo-pyridin-2-yl)amine for treatment of cardiovascular disorders
05/22/2003US20030096816 Such as 2-methylsulfanyl-5-(2-phenylamino-pyrimidin-4-yl)-4-p-tolyl-thiophene-3 -carbonitrile; antiproliferative agents; stents
05/22/2003US20030096811 Such as cis-(4-dimethylaminomethyl-3-hydroxy-3-(3-methoxy-phenyl)-cyclohexanone for treatment of pain, inflammation, allergies, depression, drug/alcohol abuse, gastritis, itching, cardiovascular/repiratory diseases, epilepsy, and diarrhea
05/22/2003US20030096796 N-cyanomethyl amides which are cysteine protease inhibitors; use treating diseases associated with activity of cathepsins B, K, L or S such as autoimmune disorders, allergic disorder, allogeneic immune response, cardiovascular disorders
05/22/2003US20030096788 Adenosine derivatives
05/22/2003US20030096783 21132, a human G-protein coupled receptor family member and uses therefor
05/22/2003US20030096782 Expression profiling in the intact human heart
05/22/2003US20030096771 8-50 nucleobases targeted to a nucleic acid molecule encoding hormone-sensitive lipase to hybridize with and inhibit expression
05/22/2003US20030096761 Angiotensin converting enzyme (ACE) and/or neutral endopeptidase (NEP); organic acids and salts thereof, sodium lauryl sulfate and palmitoyl carnitine enhancers used in treating cardiovascular disorders
1 ... 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 ... 1595